Skip to main content

Table 1 Medicines identified as potential MES candidates since introduction of formal MES policy in January-2011 [35]

From: A real world example of coverage with evidence development in Australia - ipilimumab for the treatment of metastatic melanoma

Medicinea MES
Ipilimumab for metastatic melanoma (2012) • Pay for performance with rebates payable should 2 year overall survival rates in real world clinical practice in Australia not align with clinical trial data
Ivacaftor for cystic fibrosis (2014) • Pay for performance with rebates applicable for patients subsequently assessed as non-responders
Eculizumab for atypical haemolytic uraemic syndrome (2014) • Pay for performance with rebates applicable for patients who do not achieve an agreed clinical outcome over an agreed time periods
Trametinib for metastatic melanoma (2014) • Pay for performance with rebates applicable should trametinib fail to deliver claimed benefits
Crizotinib for non-small cell lung cancer (2014) • Pay for performance with rebates applicable should crizotinib fail to deliver claimed benefits
Pembrolizumab for metastatic melanoma (2015) • PBS list with provision for future clinical trial evidence to support a potential price increase
Nivolumab for non-small cell lung cancer (2016) • PBS list with provision of future evidence to confirm effectiveness of nivolumab in NSCLC patients ≥75 years of age
  1. aMedicines considered by the PBAC between January 2011 and November 2016